Citius Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTXR$0.54+0.5%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Checking your notes…
| Preferred · Common Stock · Additional Paid-In · Accumulated · Total Citius Pharmaceuticals, Inc. Stockholders’ · Non-Controlling · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Stock | Shares | Amount | Capital | Deficit | Equity | Interest | Equity | |
| Balance, September 30, 2023 | — | 6,354,371 | $6,354 | $253,056,133 | $(162,231,379) | $90,831,108 | $600,380 | $91,431,488 |
| Issuance of common stock for services | — | 15,479 | 15 | 284,161 | — | 284,176 | — | 284,176 |
| Issuance of common stock upon exercise of stock options | — | 2,082 | 2 | (2) | — | — | — | — |
| Sale of common stock, net of costs | — | 875,311 | 876 | 13,802,808 | — | 13,803,684 | — | 13,803,684 |
| Stock-based compensation expense | — | — | — | 11,839,678 | — | 11,839,678 | — | 11,839,678 |
| Merger, net of transaction costs of $2,358,780 | — | — | — | (3,831,357) | — | (3,831,357) | — | (3,831,357) |
| Minority interest from Merger | — | — | — | (3,711,000) | — | (3,711,000) | 3,711,000 | — |
| Net loss | — | — | — | — | (39,425,839) | (39,425,839) | — | (39,425,839) |
| Net loss attributable to noncontrolling interest | — | — | — | — | 287,000 | 287,000 | (287,000) | — |
| Balance, September 30, 2024 | — | 7,247,243 | 7,247 | 271,440,421 | (201,370,218) | 70,077,450 | 4,024,380 | 74,101,830 |
| November 2024 sale of common stock, net of costs of $425,949 | — | 480,000 | 480 | 2,573,571 | — | 2,574,051 | — | 2,574,051 |
| January 2025 sale of common stock, net of costs of $342,833 | — | 743,496 | 744 | 2,656,423 | — | 2,657,167 | — | 2,657,167 |
| April 2025 sale of common stock and pre-funded warrants, net of costs of $256,116 | — | 465,000 | 465 | 1,743,292 | — | 1,743,757 | — | 1,743,757 |
| June 2025 sale of common stock and pre-funded warrants, net of costs of $571,126 | — | 540,000 | 540 | 5,430,296 | — | 5,430,836 | — | 5,430,836 |
| July 2025 sale of common stock by Citius Oncology, net of costs of $1,453,012 | — | — | — | 3,770,278 | — | 3,770,278 | (3,776,710) | 7,546,988 |
| September 2025 sale of common stock by Citius Oncology, net of costs of $1,380,146 | — | — | — | 4,090,493 | — | 4,090,493 | (3,529,361) | 7,619,854 |
| Issuance of common stock for services | — | 20,000 | 20 | 26,580 | — | 26,600 | — | 26,600 |
| Issuance of common stock upon exercise of pre-funded warrants | — | 5,654,131 | 5,654 | (5,088) | — | 566 | — | 566 |
| Sales of common stock under at the market offering agreement, net of costs | — | 2,917,874 | 2,918 | 4,727,011 | — | 4,729,929 | — | 4,729,929 |
| Sale of Series A preferred stock | 1 | — | — | 100 | — | 100 | — | 100 |
| Redemption of Series A preferred stock | (1) | — | — | (100) | — | (100) | — | (100) |
| Stock-based compensation expense | — | — | — | 9,882,962 | — | 9,882,962 | 953,329 | 10,836,291 |
| Net loss | — | — | — | — | (39,740,269) | (39,740,269) | — | (39,740,269) |
| Net loss attributable to noncontrolling interest | — | — | — | — | 2,306,358 | 2,306,358 | (2,306,358) | — |
| Balance, September 30, 2025 | — | 18,067,744 | $18,068 | $306,336,239 | $(238,804,129) | $67,550,178 | $9,977,422 | $77,527,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.